IRCMS International Research Center for Medical Sciences


Goro Sashida
M.D., Ph.D.


Selected Research Articles:

  1. Bai J, Yokomizo-Nakano T, Kubota SSun Y, Kanai A, Iimori M, Harada H, Iwama A, Sashida G. Overexpression of Hmga2 activates Igf2bp2 and remodles transcriptional program of Tet2-deficient stem cells in myeloid transformation. Oncogene 2021. [e-published]
  2. Yokomizo-Nakano T, Kubota S, Bai J, Hamashima A, Morii M, Sun Y, Katagiri S, Iimori M, Kanai A, Tanaka D, Oshima M, Harada Y, Ohyashiki K, Iwama A, Harada H, Osato M, Sashida G. Overexpression of RUNX3 represses RUNX1 to drive transformation of myelodysplastic syndrome. Cancer Res 2020; 80(12): 2523-2536.
  3. Shide K, Kameda T, Kamiunten A, Ozono Y, Tahira Y, Yokomizo-Nakano T, Kubota S, Ono M, Ikeda K, Sekine M, Akizuki K, Nakamura K, Hidaka T, Kubuki Y, Iwakiri H, Hasuike S, Nagata K, Sashida G, Shimoda K. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms. Blood 2020; 136(1): 106-118.
  4. Kuan JW, Su AT, Tay SP, Fong IL, Kubota S, Su'ut L, Osato M, Sashida G. Low prevalence of the BCR-ABL1 fusion gene in a normal population in southern Sarawak. Int J Hematol 2020; 111(2): 217-224.
  5. Kubota S, Tokunaga K, Umezu T, Yokomizo-Nakano T, Sun Y, Oshima M, Tan KT, Yang H, Kanai A, Iwanaga E, Asou N, Maeda T, Nakagata N, Iwama A, Ohyashiki K, Osato M, Sashida G. Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. Nature Commun 2019; 10: 1653.
  6. Wang C, Oshima M, Sato D, Matsui H, Kubota S, Aoyama K, Nakajima-Takagi Y, Koide S, Matsubayashi J, Mochizuki-Kashio M, Nakano-Yokomizo T, Bai J, Nagao T, Kanai A, Iwama A, Sashida G. Ezh2 loss propagates hypermethylation at T-cell differentiation-regulating genes to promote leukemic transformation. J Clin Invest 2018; 128(9): 3872-3886.
  7. Hayashi Y, Zhang Y, Yokota A, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger G, Wang J, Dong Y, Zhou Y, Wang J, Wu LY, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale L, Harada H, Shih LY, Tse W, Bridges J, Caligiuri M, Huang T, Zheng Y, Witte D, Wang Q, Qu CK, Salomonis N, Grimes L, Nimer S, Xiao Z, Huang G. Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discovery 2018 8(11):1438-1457.
  8. Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia 2017; 31(4): 861-871.
  9. Sashida G#, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, Mochizuki-Kashio M, Harada H, Shimoda K, Iwama A#. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med 2016; 213(8): 1459-1477. #corresponding authors
  10. Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, Iwama A.  Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-depenedent manner.  Blood 2015; 126(10): 1172-83.
  11. Wang C, Oshima M, Sashida G, Tomioka T, Hasegawa N, Mochizuki-Kashio M, Nakajima-Takagi Y, Kusunoki Y, Kyoizumi S, Imai K, Nakachi K, Iwama A. Non-Lethal Ionizing Radiation Promotes Aging-Like Phenotypic Changes of Human Hematopoietic Stem and Progenitor Cells in Humanized Mice.  PLoS One 2015; 10(7): e0132041.
  12. Sashida G#, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto T, Hayashi Y, Suzuki K, Nakajima H, Inaba T, Koseki H, Huang G, Kitamura T, Iwama A#. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nature Commun 2014; 5: 4177. #corresponding authors
  13. Wang C, Sashida G, Saraya A, Ishiga R, Koide S, Oshima M, Isono K, Koseki H, Iwama A. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. Blood 2014; 123(21): 3336-43.
  14. Muto T#, Sashida G#, Oshima M#, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, Iwama A. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013; 210(12): 2627-39. #Equal contribution
  15. Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, Iwama A. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 2012; 120(5): 1107-17.
  16. Zhang Y#, Yan X#, Sashida G#, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, Grimes HL, Caligiuri MA, Huang G. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood 2012; 120(5): 1118-29. # Equal contribution
  17. Sashida G, Bae N, Di Giandomenico S, Asai T, Gurvich N, Bazzoli E, Liu Y, Huang G, Zhao X, Menendez S, Nimer SD. The Mef/Elf4 transcription factor finetunes the DNA damage response. Cancer Res 2011; 71(14): 4857-65.
  18. Huang G, Zhao X, Wang L, Elf S, Xu H, Zhao X, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, Yang Y, Yan X, Zhang P, Tenen DG, Osato M, Hsieh JJ, Nimer SD. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood 2011; 118(25): 6544-52.
  19. Miyata Y, Liu Y, Jankovic V, Sashida G, Lee JM, Shieh JH, Naoe T, Moore M, Nimer SD. Cyclin C regulates human hematopoietic stem/progenitor cell quiescence. Stem Cells 2010; 28(2): 308-317.
  20. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, Antipin J, Reva B, Koff A, Nimer SD. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4(1): 37-48.
  21. Sashida G, Liu Y, Elf S, Miyata Y, Ohyashiki K, Izumi M, Menendez S, Nimer SD. ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16 activation to promote transformation. Mol Cell Biol 2009; 29(13): 3687-99.
  22. Tauchi T, Shin-Ya K, Sashida G, Sumi M, Okabe S, Ohyashiki JH, Ohyashiki K. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 2006; 25: 5719-25.
  23. Nakajima A, Tauchi T, Sashida G, Sumi M, Abe K, Yamamoto K, Ohyashiki JH, Ohyashiki K. Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 2003; 17: 560-567.
  24. Sashida G, Ohyashiki JH, Nakajima A, Sumi M, Kawakubo K, Tauchi T, Ohyashiki K. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 2003; 9: 1489-1496.
  25. Sashida G, Ohyashiki JH, Ito Y, Ohyashiki K. Monoclonal constitution of neutrophils detected by PCR-based human androgen receptor gene assay in a subset of idiopathic thrombocytopenic purpura patients. Leuk Res 2002; 26: 825-830.



  1. Sashida G, Oshima M, Iwama A. Deregulated Polycomb functions in myeloproliferative neoplasms. Int J Hematol 2019; 110(2): 170-178.
  2. Sashida G, Iwama A. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. Int J Hematol 2017; 105(1): 23-30.
  3. Sashida G, Iwama A. Epigenetic regulation of hematopoiesis. Int J Hematol 2012; 96(4): 405-12.
  4. Sashida G, Bazzoli E, Menendez S, Liu Y, Nimer SD. The oncogenic role of the ETS transcription factors MEF and ERG. Cell Cycle 2010; 9: 3457-9.
  5. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21: 680-687.

Link to a complete list of Goro Sashida's publications.